中国互联网医院降压西药与中成药处方特征及指南一致性横断面研究
该横断面研究基于银川互联网医疗监管平台87家企业主导互联网医院2018年1月至2021年3月数据,纳入787,209次高血压诊断且开具至少一种口服降压药的就诊。结果显示93.75%单独处方西药、4.72%单独中成药、1.52%中西药联用;西药处方多数与指南一致,但中成药仅181次(0.37%)含中医证型诊断,38种中成药中仅7种为指南推荐,常用品种及联用方案多未被指南推荐。
要点
- 互联网医院降压西药处方指南一致性较好,CCB最常用(38.50%),硝苯地平占19.67%。
- 中成药处方普遍缺乏中医辨证,仅0.37%含证型诊断,38种中仅7种指南推荐。
- 常用中成药九强脑立清(17.67%)与真菊降压片(14.74%)均非指南推荐。
核心结论
- 互联网医院降压西药处方特征与线下医院接近且指南一致性相对满意,但中成药存在缺乏辨证、频开非推荐品种及重复治疗等问题,需加强管理。
研究设计与样本
- 横断面分析,数据来自银川互联网医疗监管平台,覆盖87家企业主导互联网医院,时间2018年1月1日至2021年3月31日。
- 纳入高血压诊断且开具至少一种口服降压药(西药或中成药)的就诊,共787,209次。
- 采用描述性统计、关联规则分析和指南一致性评估,对照国际与中国高血压指南推荐。
主要发现
- 93.75%就诊单独处方西药,4.72%单独中成药,1.52%中西药联用。
- 西药中最常用类别为钙通道阻滞剂(CCB,38.50%),最常用单药为硝苯地平(19.67%)。
- 中成药处方中仅181次(0.37%)包含中医证型诊断。
- 38种降压中成药中仅7种为指南推荐;最常用九强脑立清(17.67%)和真菊降压片(14.74%)均非指南推荐。
- 两种中成药联用常见,但无一被指南推荐;最常见联用为九强脑立清+强力定眩片/胶囊(支持度8.65%,置信度0.44%)。
关键数值与推荐
- 西药处方多数与高血压指南一致。
- 中成药指南推荐品种:38种中仅7种被指南推荐。
- 中成药联用方案:常见双中成药联用均未被指南推荐。
临床怎么用
- 互联网医院开具降压中成药时应要求记录中医证型诊断,避免无辨证用药。
- 优先选用指南推荐的中成药品种,减少非推荐品种及重复联用。
- 对中西药联用处方应评估重复治疗风险,参照指南优化降压方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Internet hospitals have emerged as a vital approach for patients seeking treatment for hypertension, with a significant increase in antihypertensive medication prescriptions through these innovative models. However, prescribing characteristics and guideline concordance of these prescriptions remain unclear. This study aim to analyze the prescribing characteristics of Western medicine (WM) and Chinese patent medicine (CPM) for hypertension and assess their concordance with hypertension guidelines in Internet hospitals in China, providing insights for optimizing antihypertensive CPM management. METHODS: A cross-sectional analysis was conducted using data from the Yinchuan Internet Medical Regulatory Platform (YIMRP) covering 87 enterprise-led Internet hospitals in China from 1 January 2018, to 31 March 2021. Visits diagnosed with hypertension and prescribed at least one oral antihypertensive medication (either WM or CPM) were included. Guideline concordance was evaluated by comparing prescribed individual antihypertensive WM and CPM in Internet hospitals with international and Chinese hypertension guidelines recommendations. Statistical analyses included descriptive statistics, association rule analysis, and guideline concordance assessment. RESULTS: Among the 787,209 visits, 93.75% were prescribed WM alone, 4.72% CPM alone, and 1.52% a combination of CPM and WM. Calcium channel blockers (CCBs) (38.50%) was the most prescribed WM class, with nifedipine (19.67%) being the most common individual medication. Most prescriptions of antihypertensive WM were guideline-concordant. Among CPM prescriptions, only 181 (0.37%) included traditional Chinese medicine (TCM) syndrome diagnoses. Of the 38 prescribed antihypertensive CPM, only 7 were guideline-recommended. The most frequently prescribed CPM were Jiuqiang Naoliqing (17.67%), and Zhenju Jiangya tablet (14.74%), neither of which was recommended by the guidelines. The combinations of two CPM were frequently prescribed, but none of these combinations were recommended by guidelines. The most common dual CPM combination was Jiuqiang Naoliqing + Qiangli Dingxuan tablet/capsule (support 8.65%, confidence 0.44%). CONCLUSION: The prescribing characteristics of antihypertensive WM in Internet hospitals closely align with those in offline hospitals with relatively satisfactory guideline concordance. However, some issues persist in antihypertensive CPM prescriptions, including the lack of TCM syndrome differentiation, frequent prescription of non-recommended CPM, and duplicate therapies. Strengthening CPM management in Internet hospitals is essential for optimizing hypertension care.
引用
- Zhou T, Liao X, Zuo J, et al. Prescribing characteristics and guideline concordance of antihypertensive western and Chinese patent medicine in Internet hospitals in China: a cross-sectional study. Front Pharmacol. 2025. PMID: 40371350. doi:10.3389/fphar.2025.1580787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。